Over recent years, GLP-1-receptor-agonists (GLP-1-RA) have gained significant attention not only for their antidiabetic properties but also for their weight reducing effects [3]
Adding more diluent lowers the concentration, so you need to draw a larger volume for the same dose
And it essentially is a mirror image of the weight loss and metabolic benefits seen with tirzepatide at 48 weeks
Operationally, GLP-1 therapies have also increased the administrative burden
These are separate NDA submissions with separate label claims even though the molecule is the same
Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB